Calcitonin receptors of human osteoclastoma.
Osteoclast-rich cultures were prepared by disaggregation of osteoclastomas (giant cell tumour of bone) and settlement onto glass or plastic surfaces. Autoradiography using [125I]-salmon calcitonin ([125I]-sCT) revealed specific binding only to multinucleate giant cells (osteoclasts) and a minor population of mononuclear cells. [125I]-sCT competitive binding studies indicated a Kd of 5 x 10(-10) M and receptor number of approximately 1 million sites/osteoclast. sCT treatment resulted in a dose-dependent rise in cAMP (EC50 10(-10) M). Homogenates of an osteoclastoma also demonstrated specific binding of [125I]-sCT. Chemical cross-linking of a labelled synthetic sCT derivative. [125I]-[Arg11,18,Lys14]-sCT, using disuccinimidyl suberate, resulted in labelling of a receptor component of approximate Mr 85-90,000. The multinucleate giant cells (osteoclasts) of human osteoclastomas possess large number of CT receptors which exhibit the same binding kinetics and apparent Mr as those of other CT target cells.
Nicholson
G C
GC
University of Melbourne, Department of Medicine, Repatriation General Hospital, Heidelberg, Victoria, Australia.
Horton
M A
MA
Sexton
P M
PM
D'Santos
C S
CS
Moseley
J M
JM
Kemp
B E
BE
Pringle
J A
JA
Martin
T J
TJ
D001859:Bone Neoplasms / Q000032:analysis*; D005870:Giant Cell Tumors / Q000032:analysis*; D006801:Humans; D008858:Microscopy, Phase-Contrast; D008970:Molecular Weight; D018003:Receptors, Calcitonin; D011956:Receptors, Cell Surface / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000032:analysis
D018003:Receptors, Calcitonin; D011956:Receptors, Cell Surface